May 15, 2024
Dr. Wagenblast Receives NCI Grant for “Intrinsic and Extrinsic Factors Contributing to Trisomy 21 Preleukemia”
Congratulations to Elvin Wagenblast, PhD, who received an R01 from the National Cancer Institute for “Intrinsic and Extrinsic Factors Contributing to Trisomy 21 Preleukemia.” Children with Down syndrome have a significantly increased risk of developing preleukemia during early childhood compared to children without Down syndrome and this grant aims to determine the molecular mechanisms that underlie this predisposition.Congratulations to Elvin Wagenblast, PhD, who received an R01 from the National Cancer Institute for “Intrinsic and Extrinsic Factors Contributing to Trisomy 21 Preleukemia.” Children with Down syndrome have a significantly increased risk of developing preleukemia during early childhood compared to children without Down syndrome and this grant aims to determine the molecular mechanisms that underlie this predisposition.
May 10, 2024
New Research by Dr. Franco Izzo: Linking Genotypes to Chromatin Accessibility in Single Cells
New article by Franco Izzo, PhD, in Nature: "Mapping Genotypes to Chromatin Accessibility Profiles in Single Cells". By linking somatic mutations with epigenetic profiles, GoT-ChA lays the groundwork for exploring connections between mutations and epigenetic changes in both malignant and non-malignant settings.
January 15, 2024
Welcome Dr. Franco Izzo: Innovator in Single-Cell Multi-Modal Technologies and Epigenetics
We are thrilled to welcome Franco Izzo, PhD, who joined the CABCT and ISSMS as our newest Assistant Professor. Specializing in cutting-edge single-cell multi-modal technologies, the Izzo lab aims to unravel how somatic mutations drive epigenetic deregulation in hematological malignancies.
December 19, 2023
Dr. Wagenblast Named Pew-Stewart Scholar for Groundbreaking Leukemia Research
Elvin Wagenblast, PhD, was named a Pew-Stewart Scholars for Cancer Research from the Pew Charitable Trusts and the Alexander and Margaret Stewart Trust. This work is focused on establishing a platform to study the differences between pediatric and adult acute myeloid leukemia.
December 12, 2023
Dr. Sturgeon Secures Grant for Pioneering Stem Cell and Immunity Research
Christopher Sturgeon, PhD, received an R01 from the National Institute of Biomedical Imaging and Bioengineering for “Engineering pluripotent stem cells to evade and promote immunity”. This Multi-PI mechanism aims to develop novel strategies to confer adaptive immunity via genetic engineering and stem cell differentiation strategies.
March 15, 2023
Dr. Wagenblast Wins Runyon-Rachleff Innovation Award for Groundbreaking Childhood Leukemia Research
Elvin Wagenblast, PhD, received the Runyon-Rachleff Innovation Award from the Damon Runyon Cancer Research Foundation. The goal of this project is to understand the cellular and evolutionary dependency of childhood leukemia.